Poseida promotes cell therapy president to CEO; After IPO, Neumora appoints R&D chief
→ The CEO post is changing hands once again at Poseida, as Kristin Yarema gets promoted to the top spot on Jan. 1 and Mark Gergen will take on the role of executive chairman. At the conclusion of her seven years with Amgen (2013-20), Yarema was bumped up to VP & therapeutic area head for global product strategy & commercial innovation in hematology-oncology. She then spent more than two years at Atara Biotherapeutics as commercial chief before becoming president of cell therapy at Poseida in April. Gergen, the former CBO at the San Diego CAR-T biotech, succeeded Eric Ostertag as chief executive on Feb. 1, 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.